PD-1 and PD-L1 Inhibitors Market by Application and Geography - Forecast and Analysis 2022-2026

The PD-1 and PD-L1 inhibitors market share is expected to increase by USD 49.34 billion from 2021 to 2026, and the market’s growth momentum will accelerate at a CAGR of 19.31%.

This PD-1 and PD-L1 inhibitors market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers PD-1 and PD-L1 inhibitors market segmentation by application (solid tumors and blood-related tumors) and geography (North America, Europe, Asia, and Rest of World (ROW)). The programmed cell death protein 1 & programmed cell death ligand 1 inhibitors market report also offers information on several market vendors, including Akeso Inc., Alphamab Oncology, Amgen Inc., AstraZeneca Plc, BeiGene Ltd., Bristol Myers Squibb Co., Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Innovent Biologics Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Merck and Co. Inc., Merck KGaA, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi, and Shanghai Jhunsi Biosciences Ltd. among others.

What will the PD-1 and PD-L1 Inhibitors Market Size be During the Forecast Period?

Download Report Sample to Unlock the PD-1 and PD-L1 Inhibitors Market Size for the Forecast Period and Other Important Statistics

 

PD-1 and PD-L1 Inhibitors Market: Key Drivers, Trends, and Challenges

The increasing prevalence of cancer is notably driving the PD-1 and PD-L1 inhibitors market growth, although factors such as the high cost of available PD-1 and PD-L1 inhibitors may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the PD-1 and PD-L1 inhibitors industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key PD-1 and PD-L1 Inhibitors Market Driver

One of the key factors driving growth in the PD-1 and PD-L1 inhibitors market is the increasing prevalence of cancer. The prevalence of cancer witnessed a significant rise in recent years globally, and the global oncology therapeutics market witnessed the approval of various novel therapies. The gap between the demand and supply of these therapies has resulted in a huge unmet need, which has created an opportunity for vendors to conduct a study on drugs such as PD-1 and PD-L1 inhibitors. The new cases of cancer have increased significantly in recent years owing to factors such as the increasing geriatric population and changes in lifestyle. Various pharmaceutical companies are conducting heavy research on developing novel PD-1 and PD-L1 inhibitors to meet this demand, and the approval of these drugs has risen in recent years. The increasing approvals of these inhibitors for the treatment of various cancer indications are expected to increase their demand, which is expected to lead to the growth of the global PD-1 and PD-L1 inhibitors market.

Key PD-1 and PD-L1 Inhibitors Market Trend

The strong pipeline is a PD-1 and PD-L1 inhibitors market trend that is expected to have a positive impact in the coming years. The global Programmed cell death protein 1 & programmed cell death ligand 1 inhibitors market witnesses the presence of various large pharmaceutical players with novel therapies in the pipeline for the treatment of various types of cancers. The superior efficacy of approved PD-1 and PD-L1 inhibitors has led various companies to conduct research on more advanced therapies to treat various cancer indications. As a result, the demand for these inhibitors is increasing, with highly promising therapies in the late stages of clinical trials. Although certain cancer medicines are still in the early phases of development, vendors benefit from specific drug designations granted by regulatory authorities such as the US FDA and EMA, which assist the drugs in obtaining faster clearance. Such novel drugs are expected to receive marketing clearance for various indications, and the market in focus is expected to witness growth.

Key PD-1 and PD-L1 Inhibitors Market Challenge

The high cost of available PD-1 and PD-L1 inhibitors will be a major challenge for the PD-1 and PD-L1 inhibitors market during the forecast period. The high cost associated with the treatment using PD-1 and PD-L1 inhibitor drugs is the major challenge faced by the global PD-1 and PD-L1 inhibitors market. The high cost of cancer treatment is mainly due to hospitalization, laboratory tests, and the administration of novel PD-1 and PD-L1 inhibitor therapeutics. The treatment cost of PD-1 and PD-L1 inhibitor therapeutics also depends on the stage of cancer. The cost of the PD-1 and PD-L1 inhibitors treatment is very high in developing and underdeveloped countries. This is leading to an increase in the preference for alternative treatment options such as surgeries, which is the most common treatment for solid and blood-related tumors. Therefore, such high treatment costs reduce patient adherence to treatment, thereby hindering the growth of the focused market.

This Programmed cell death protein 1 & programmed cell death ligand 1 inhibitors market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.

Parent Market Analysis

Technavio categorizes the global PD-1 and PD-L1 inhibitors market as a part of the pharmaceutical market within the overall healthcare industry. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the programmed cell death protein 1 & programmed cell death ligand 1 inhibitors market during the forecast period.

Who are the Major PD-1 and PD-L1 Inhibitors Market Vendors?

The report analyzes the market’s competitive landscape and offers information on several market vendors, including:

 

• Akeso Inc.
• Alphamab Oncology
• Amgen Inc.
• AstraZeneca Plc
• BeiGene Ltd.
• Bristol Myers Squibb Co.
• Chia Tai Tianqing Pharmaceutical Group Co. Ltd.
• Eli Lilly and Co.
• F. Hoffmann La Roche Ltd.
• Gilead Sciences Inc.
• GlaxoSmithKline Plc
• Innovent Biologics Inc.
• Jiangsu Hengrui Pharmaceuticals Co. Ltd.
• Merck and Co. Inc.
• Merck KGaA
• Novartis AG
• Pfizer Inc.
• Regeneron Pharmaceuticals Inc.
• Sanofi
• Shanghai Jhunsi Biosciences Ltd.

 

This statistical study of the PD-1 and PD-L1 inhibitors market encompasses successful business strategies deployed by the key vendors. The programmed cell death protein 1 & programmed cell death ligand 1 inhibitors market is fragmented and the vendors are deploying organic and inorganic growth strategies to compete in the market.

Product Insights and News

• amgen.com - The company offers PD-1 and PD-L1 inhibitors namely Talimogene Laherparepvec.

• amgen.com - The unified segment focuses on discovering, developing, manufacturing, and delivering innovative human therapeutics.

To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The PD-1 and PD-L1 inhibitors market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.

PD-1 and PD-L1 Inhibitors Market Value Chain Analysis

Our report provides extensive information on the value chain analysis for the PD-1 and PD-L1 inhibitors market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

Which are the Key Regions for PD-1 and PD-L1 Inhibitors Market?

For more insights on the market share of various regions Request PDF Sample now!

51% of the market’s growth will originate from North America during the forecast period. US and Canada are the key markets for PD-1 and PD-L1 inhibitors in North America. Market growth in this region will be slower than the growth of the market in the European and Asian regions.

The sales of approved therapeutics and the increasing prevalence of various solid tumors and blood-related tumors in the region will facilitate the PD-1 and PD-L1 inhibitors market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

COVID Impact and Recovery Analysis

In 2020, the outbreak of COVID-19 negatively impacted the market in focus in North America. Owing to the adverse effects of the pandemic, numerous cancer treatment facilities were compelled to lay off employees. Thus, numerous vendors in the market in focus faced shortages in personnel and raw materials that further led to disruptions in the supply chains for the production of PD-1 and PD-L1 inhibitor drugs. However, in the second half of 2020, several market vendors offered PD-1 and PD-L1inhibitor drugs through digital channels, which enabled the market to deal with the negative effects of the pandemic by registering growth through online sales. Furthermore, in 2021, owing to large-scale vaccination drives and the resumption of operations in healthcare units, larger inflows of patients resumed treatment of melanoma in healthcare facilities in North America as compared to 2020 due to the removal of lockdown restrictions. 

What are the Revenue-generating Application Segments in the PD-1 and PD-L1 Inhibitors Market?

To gain further insights on the market contribution of various segments Request PDF Sample

The PD-1 and PD-L1 inhibitors market share growth by the blood-related tumors segment will be significant during the forecast period. The blood-related tumor segment is expected to grow significantly during the forecast period owing to the strong prevalence of leukemia and various types of lymphomas globally.

This report provides an accurate prediction of the contribution of all the segments to the growth of the programmed cell death protein 1 (PD-1) & programmed cell death ligand 1 (PD-L1) inhibitors market size and actionable market insights on post COVID-19 impact on each segment.

 

Programmed Cell Death Protein 1 & Programmed Cell Death Ligand 1 Inhibitors Market Scope
Report Coverage	Details
Page number	120
Base year	2021
Forecast period	2022-2026
Growth momentum & CAGR	Accelerate at a CAGR of 19.31%
Market growth 2022-2026	$ 49.34 billion
Market structure	Fragmented
YoY growth (%)	18.6
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 51%
Key consumer countries	US, Canada, Germany, UK, and France
Competitive landscape	Leading companies, Competitive strategies, Consumer engagement scope
Key companies profiled	Akeso Inc., Alphamab Oncology, Amgen Inc., AstraZeneca Plc, BeiGene Ltd., Bristol Myers Squibb Co., Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Innovent Biologics Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Merck and Co. Inc., Merck KGaA, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi, and Shanghai Jhunsi Biosciences Ltd.
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period.
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request PDF sample

What are the Key Data Covered in this PD-1 and PD-L1 Inhibitors Market Report?

• CAGR of the market during the forecast period 2022-2026
• Detailed information on factors that will drive PD-1 and PD-L1 inhibitors market growth during the next five years
• Precise estimation of the PD-1 and PD-L1 inhibitors market size and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behavior
• The growth of the PD-1 and PD-L1 inhibitors industry across North America, Europe, Asia, and Rest of World (ROW)
• A thorough analysis of the market’s competitive landscape and detailed information on vendors
• Comprehensive details of factors that will challenge the growth of programmed cell death protein 1 (PD-1) & programmed cell death ligand 1 (PD-L1) inhibitors market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch